COMPANY

Souffle Therapeutics

Keywords: facioscapulohumeral muscular dystrophy heart failure metabolic SFL-0821

Location: Watertown, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

2026-09 Trial start Phase 1/Phase 2: A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD source ↗

2028-03 (ESTIMATED) · Phase 1/Phase 2 · A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD · NCT07798609

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07798609	A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD	Phase 1/Phase 2	Recruiting	2026-09	2028-03 (estimated)